Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: ripples from SVB’s failure; Karuna’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 24 March 2023, including: ripples from SVB’s failure; Karuna Therapeutics, Inc.’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Is SVB Failure A Sign Of More Uncertainty On The Horizon?" - Scrip, 21 Mar, 2023.)
(Also see "Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint" - Scrip, 20 Mar, 2023.)
(Also see "Pharma Giants Urge Biotechs To Get In Touch As Early As Possible" - Scrip, 20 Mar, 2023.)
(Also see "The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses" - Scrip, 22 Mar, 2023.)
(Also see "COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says" - Scrip, 21 Mar, 2023.)